

Cancer – Connecticut

PRESENTED BY AMERICA'S PHARMACEUTICAL RESEARCH COMPANIES

More Than 70 Medicines in Biopharmaceutical Pipeline Target Several Types of Cancer


Few things cause patients more fear and uncertainty than a cancer diagnosis. But today—because of a steady stream of new and improved medicines and treatments—cancer increasingly can be managed and even beaten. President Obama has called for a cancer cure in our lifetime, patients and their families are looking for more and better treatments, and America's pharmaceutical research and biotechnology companies are responding.

Connecticut pharmaceutical and biotechnology companies are playing a role in the battle against cancer. Of the 861 medicines now being developed nationwide to treat or prevent cancer, 74 are being developed by Connecticut companies. All of the medicines listed in this report are being developed by companies with a physical presence in Connecticut and are in human clinical trials or awaiting approval by the U.S. Food and Drug Administration.

Cancer is the second leading cause of death in Connecticut, accounting for 6,994 deaths in 2006. The medicines in development include 17 for lung cancer, the leading cause of cancer death in Connecticut; nine for colorectal cancer, the second leading cause of cancer death in Connecticut; 13 for breast cancer, which killed 537 women in Connecticut in 2006; four for pancreatic cancer, which killed 478 Connecticut residents in 2006; and 13 for prostate cancer, which killed 371 Connecticut men in 2006. Additional medicines target brain cancer, kidney cancer, leukemia, ovarian cancer, skin cancer, and others. In addition, companies are working on medicines to improve the quality of life for cancer patients.

This commitment to patients and research is at the core of the remarkable progress made in the past decade fighting cancer that has led to declines in both cancer cases and cancer deaths. Death rates for eight of the top 10 cancers

MEDICINES IN DEVELOPMENT FOR CANCER—CONNECTICUT*



*Some medicines are listed in more than one category.

CANCER DEATH IN CONNECTICUT, 2006

All Cancers	6,994
Lung Cancer	1,822
Colorectal Cancer	642
Breast Cancer (female)	537
Pancreatic Cancer	478
Prostate Cancer	371
Leukemia	277
Ovarian Cancer	206
Bladder Cancer	206
Brain Cancer	152
Uterine Cancer	103
Skin Cancer	99
Lip and Oral Cancer	74
Cervical Cancer	38

Source: Office of Vital Records, Connecticut Department of Public Health, 2006

remained level or declined during the 1990s, according to a *Journal of the National Cancer Institute* report.

Despite progress, cancer remains the second leading cause of death by disease in the United States, exceeded only by heart disease. In 2008, some 565,650 Americans were expected to die of cancer—more than 1,500 people a day. The hundreds of new medicines to treat cancer now being developed by the pharmaceutical research industry demonstrate our commitment to meeting patient needs. They are our best hope for stemming the toll of cancer-related deaths.

Billy Tauzin
President and CEO
PhRMA

Medicines in Development for Cancer— Connecticut

CANCER

Product Name	Sponsor	Indication	Development Status*
Ablvax™ (VAXICO)	Breakthrough Therapeutics <i>Greenwich, CT</i>	chronic myeloid leukemia (CML)	Phase II
AG-14699	Pfizer <i>New York, NY</i> <i>Groton, CT</i> <i>New London, CT</i>	breast, ovarian cancers	Phase II (860) 732-5156
AG-24322	Pfizer <i>New York, NY</i> <i>Groton, CT</i> <i>New London, CT</i>	unspecified cancer	Phase I (860) 732-5156
ALXN-6000	Alexion Pharmaceuticals <i>Cheshire, CT</i>	chronic lymphocytic leukemia (CLL)	Phase I/II (203) 272-2596
Aromasin® exemestane	Pfizer <i>New York, NY</i> <i>Groton, CT</i> <i>New London, CT</i>	breast cancer prevention	Phase III (860) 732-5156
axitinib	Pfizer <i>New York, NY</i> <i>Groton, CT</i> <i>New London, CT</i>	kidney cancer	Phase III (860) 732-5156
		colorectal cancer, non-small-cell lung cancer (NSCLC), thyroid cancer	Phase II (860) 732-5156
		solid tumors	Phase I (860) 732-5156
BAY 73-4506	Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i> <i>West Haven, CT</i>	kidney cancer	Phase II (888) 842-2937
BI 2536	Boehringer Ingelheim Pharmaceuticals <i>Ridgefield, CT</i>	non-Hodgkin's lymphoma	Phase I (800) 243-0127
BI 6727	Boehringer Ingelheim Pharmaceuticals <i>Ridgefield, CT</i>	solid tumors	Phase I (800) 243-0127
BI 831266	Boehringer Ingelheim Pharmaceuticals <i>Ridgefield, CT</i>	solid tumors	Phase I (800) 243-0127

* For more information about a specific medicine in this report, please call the telephone number listed.

CANCER

Product Name	Sponsor	Indication	Development Status
BIBF 1120	Boehringer Ingelheim Pharmaceuticals <i>Ridgefield, CT</i>	NSCLC	Phase III (800) 243-0127
		solid tumors	Phase I (800) 243-0127
BIBW 2992	Boehringer Ingelheim Pharmaceuticals <i>Ridgefield, CT</i>	NSCLC	Phase II/III (800) 243-0127
		breast, head/neck cancers	Phase II (800) 243-0127
		glioblastoma	Phase I/II (800) 243-0127
BMS-641988 (androgen receptor antagonist)	Bristol-Myers Squibb <i>Princeton, NJ</i> <i>Wallingford, CT</i>	prostate cancer	Phase I (212) 546-4000
BMS-663513 (anti-CD137 antibody)	Bristol-Myers Squibb <i>Princeton, NJ</i> <i>Wallingford, CT</i>	second-line melanoma	in clinical trials (212) 546-4000
BMS-690514 (ErbB/VEGF receptor inhibitor)	Bristol-Myers Squibb <i>Princeton, NJ</i> <i>Wallingford, CT</i>	lung cancer, solid tumors	in clinical trials (212) 546-4000
BMS-753493 (epothilone-folate)	Bristol-Myers Squibb <i>Princeton, NJ</i> <i>Wallingford, CT</i>	ovarian cancer	in clinical trials (212) 546-4000
BMS-754807 (IGF-1R antagonist)	Bristol-Myers Squibb <i>Princeton, NJ</i> <i>Wallingford, CT</i>	solid tumors	in clinical trials (212) 546-4000
BMS-833923 (SMO inhibitor)	Bristol-Myers Squibb <i>Princeton, NJ</i> <i>Wallingford, CT</i> Exelixis <i>South San Francisco, CA</i>	solid tumors	Phase I (212) 546-4000
BMS-844203 (VEGF inhibitor- adnectin)	Bristol-Myers Squibb <i>Princeton, NJ</i> <i>Wallingford, CT</i>	glioblastoma	Phase II (212) 546-4000
		solid tumors	in clinical trials (212) 546-4000
Bonefos [®] clodronic acid	Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i> <i>West Haven, CT</i>	cancer metastases	application submitted (888) 842-2937
brivanib (VEGFR/FGFR kinase inhibitor)	Bristol-Myers Squibb <i>Princeton, NJ</i> <i>Wallingford, CT</i>	metastatic colorectal cancer, hepatocellular carcinoma	Phase III (212) 546-4000

CANCER

Product Name	Sponsor	Indication	Development Status
Campath® alemtuzumab (subcutaneous) (Orphan Drug)	Bayer HealthCare Pharmaceuticals Wayne, NJ West Haven, CT	CLL	Phase II (888) 842-2937
Camptosar® irinotecan	Pfizer New York, NY Groton, CT New London, CT	cervical, lung cancers	application submitted (860) 732-5156
		pancreatic cancer	Phase III (860) 732-5156
		prostate cancer	Phase II (860) 732-5156
Camptosar® irinotecan in combination Temodar® temozolomide	Pfizer New York, NY Groton, CT New London, CT	brain tumors (glioma, medulloblastoma)	Phase II 6 months–18 years (860) 732-5156
canertinib	Pfizer New York, NY Groton, CT New London, CT	NSCLC	Phase II (860) 732-5156
CDX-110 (Orphan Drug)	Celldex Therapeutics Needham, MA Pfizer New York, NY Groton, CT New London, CT	newly diagnosed glioblastoma	Phase II/III (781) 433-0771 (860) 732-5156
		solid tumors	Phase I (781) 433-0771 (860) 732-5156
Celebrex® celecoxib	Pfizer New York, NY Groton, CT New London, CT	bladder cancer	Phase III (860) 732-5156
		prostate cancer	Phase II (860) 732-5156
CJ-15161	Pfizer New York, NY Groton, CT New London, CT	cancer pain	Phase II (860) 732-5156
CP-751871	Pfizer New York, NY Groton, CT New London, CT	NSCLC	Phase III (860) 732-5156
		breast, colorectal cancers multiple myeloma, prostate cancer	Phase II (860) 732-5156
		sarcoma	Phase I/II (860) 732-5156
CP-870893	Pfizer New York, NY Groton, CT New London, CT	solid tumors	Phase I (860) 732-5156

CANCER

Product Name	Sponsor	Indication	Development Status
CR011-vcMMAE	CurGen <i>Branford, CT</i>	breast cancer, malignant melanoma	Phase II (888) 436-6642
ecromeximab	Life Sciences Pharmaceuticals <i>Greenwich, CT</i>	malignant melanoma (combination therapy)	Phase II (203) 422-6500
edotecarin	Pfizer <i>New York, NY</i> <i>Groton, CT</i> <i>New London, CT</i>	colorectal cancer	Phase III (860) 732-5156
elotuzumab	Bristol-Myers Squibb <i>Princeton, NJ</i> <i>Wallingford, CT</i> Facet Biotech <i>Redwood City, CA</i>	multiple myeloma	Phase I (212) 546-4000 (650) 454-1000
Erbix[®] cetuximab	Bristol-Myers Squibb <i>Princeton, NJ</i> <i>Wallingford, CT</i> Eli Lilly <i>Indianapolis, IN</i> ImClone Systems <i>New York, NY</i>	head/neck cancer ----- colorectal, esophageal, gastric, NSCLC, prostate cancers ----- bladder cancer	application submitted (212) 546-4000 (800) 545-5979 (212) 645-1405 ----- Phase III (212) 546-4000 (800) 545-5979 (212) 645-1405 ----- Phase II (212) 546-4000 (800) 545-5979 (212) 645-1405
ferucarbotran	Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i> <i>West Haven, CT</i>	liver cancer imaging	application submitted (888) 842-2937
huA33	Life Science Pharmaceuticals <i>Greenwich, CT</i>	colorectal cancer	Phase I (203) 422-6500
Idamycin[®] idarubicin	Pfizer <i>New York, NY</i> <i>Groton, CT</i> <i>New London, CT</i>	multiple myeloma, non-Hodgkin's lymphoma	Phase III (860) 732-5156
idronoxil	Marshall Edwards <i>New York, NY</i> Novogen <i>New Canaan, CT</i>	ovarian ----- fallopian tube, prostate cancers	Phase III (203) 966-2556 ----- Phase II (203) 966-2556
Ixempra[™] ixabepilone	Bristol-Myers Squibb <i>Princeton, NJ</i> <i>Wallingford, CT</i>	early breast cancer, NSCLC, pancreatic, prostate cancers	in clinical trials (212) 546-4000

CANCER

Product Name	Sponsor	Indication	Development Status
laromustine (VNP 40101M) (Orphan Drug)	Vion Pharmaceuticals <i>New Haven, CT</i>	AML (first-line therapy in elderly patients)	application submitted (203) 498-4210
		AML (combination second-line therapy)	Phase III (203) 498-4210
		glioma	Phase II (203) 498-4210
		AML (combination therapy in elderly patients), myelodysplastic syndromes (combination therapy in elderly patients)	Phase I/II (203) 498-4210
Leukine® sargramostim	Bayer HealthCare Pharmaceuticals <i>Wayne, NJ</i> <i>West Haven, CT</i>	CLL, non-Hodgkin's lymphoma, ovarian, prostate cancers, malignant melanoma	Phase II (888) 842-2937
lung cancer vaccine (NY-ESO-1)	Pfizer <i>New York, NY</i> <i>Groton, CT</i> <i>New London, CT</i>	NSCLC	Phase I (860) 732-5156
MDX-010 (ipilimumab)	Bristol-Myers Squibb <i>Princeton, NJ</i> Medarex <i>Princeton, NJ</i>	adjuvant melanoma, metastatic melanoma	Phase III (212) 546-4000
		solid tumors	in clinical trials (212) 546-4000
Nexavar® sorafenib	Bayer Pharmaceuticals <i>Wayne, NJ</i> <i>West Haven, CT</i> Onyx Pharmaceuticals <i>Emeryville, CA</i>	malignant melanoma, NSCLC	Phase III (203) 812-2000 (510) 597-6500
		breast cancer	Phase II (203) 812-2000 (510) 597-6500
PD-332991	Pfizer <i>New York, NY</i> <i>Groton, CT</i> <i>New London, CT</i>	breast cancer, multiple myeloma	Phase I/II (860) 732-5156
		mantle-cell lymphoma	Phase I (860) 732-5156
PF-299804	Pfizer <i>New York, NY</i> <i>Groton, CT</i> <i>New London, CT</i>	NSCLC	Phase II (860) 732-5156
PF-337210	Pfizer <i>New York, NY</i> <i>Groton, CT</i> <i>New London, CT</i>	unspecified cancer	Phase I (860) 732-5156
PF-477736	Pfizer <i>New York, NY</i> <i>Groton, CT</i> <i>New London, CT</i>	solid tumors	Phase I (860) 732-5156

CANCER

Product Name	Sponsor	Indication	Development Status
PF-562271	Pfizer New York, NY Groton, CT New London, CT	unspecified cancer	Phase I (860) 732-5156
PF-2341066	Pfizer New York, NY Groton, CT New London, CT	unspecified cancer	Phase I (860) 732-5156
PF-3084014	Pfizer New York, NY Groton, CT New London, CT	unspecified cancer	Phase I (860) 732-5156
PF-3446962	Pfizer New York, NY Groton, CT New London, CT	unspecified cancer	Phase I (860) 732-5156
PF-3732010	Pfizer New York, NY Groton, CT New London, CT	unspecified cancer	Phase I (860) 732-5156
PF-3814735	Pfizer New York, NY Groton, CT New London, CT	solid tumors	Phase I (860) 732-5156
PF-4217903	Pfizer New York, NY Groton, CT New London, CT	unspecified cancer	Phase I (860) 732-5156
PF-4383119 (tanezumab)	Pfizer New York, NY Groton, CT New London, CT	cancer pain	Phase II (860) 732-5156
PF-4554878	Pfizer New York, NY Groton, CT New London, CT	unspecified cancer	Phase I (860) 732-5156
PF-4856882 (CovX045)	Pfizer New York, NY Groton, CT New London, CT	solid tumors	Phase I (860) 732-5156
PF-4856884 (CovX060)	Pfizer New York, NY Groton, CT New London, CT	unspecified cancer	Phase I (860) 732-5156
PF-4929113	Pfizer New York, NY Groton, CT New London, CT	unspecified cancer	Phase I (860) 732-5156

CANCER

Product Name	Sponsor	Indication	Development Status
PHY-906	PhytoCeutica New Haven, CT	chemoprotection	Phase I/II (203) 777-3462
ProMune® agatolimod	Pfizer New York, NY Groton, CT New London, CT	NSCLC	Phase II (860) 732-5156
sagopilone	Bayer HealthCare Pharmaceuticals Wayne, NJ West Haven, CT	brain, breast, prostate cancers ----- ovarian cancer	Phase II (888) 842-2937 ----- Phase I/II (888) 842-2937
sibrotuzumab	Life Science Pharmaceuticals Greenwich, CT	colorectal, head/neck cancers, NSCLC	Phase II (203) 422-6500
Sprycel™ dasatinib	Bristol-Myers Squibb Princeton, NJ Wallingford, CT	first-line CML ----- other hematological malignancies, prostate cancer, solid tumors	Phase III (212) 546-4000 ----- in clinical trials (212) 546-4000
SU-14813	Pfizer New York, NY Groton, CT New London, CT	breast cancer	Phase II (860) 732-5156
Sutent® sunitinib	Pfizer New York, NY Groton, CT New London, CT	breast, liver cancers, NSCLC, pancreatic, prostate cancers ----- colorectal, soft tissue sarcoma, stomach cancer	Phase III (860) 732-5156 ----- Phase II (860) 732-5156
tanespimycin (Hsp90 inhibitor)	Bristol-Myers Squibb Princeton, NJ Wallingford, CT	multiple myeloma ----- solid tumors	Phase III (212) 546-4000 ----- Phase II (212) 546-4000
Trelstar® triptorelin	Watson Pharmaceuticals Corona, CA Danbury, CT	breast cancer	Phase III (951) 493-5300
tremelimumab	Pfizer New York, NY Groton, CT New London, CT	colorectal cancer, NSCLC, malignant melanoma ----- breast, kidney, prostate cancers	Phase II (860) 732-5156 ----- Phase I (860) 732-5156
Triapine®	Vion Pharmaceuticals New Haven, CT	leukemia, NSCLC, pancreatic, prostate cancers ----- hematological malignancies	Phase II (203) 498-4210 ----- Phase I (203) 498-4210

CANCER

Product Name	Sponsor	Indication	Development Status
XL-184	Bristol-Myers Squibb <i>Princeton, NJ</i> <i>Wallingford, CT</i>	medullary thyroid cancer	Phase III (212) 546-4000
	Exelixis <i>South San Francisco, CA</i>	glioblastoma	in clinical trials (212) 546-4000
XL-281 (RAF kinase inhibitor)	Bristol-Myers Squibb <i>Princeton, NJ</i> <i>Wallingford, CT</i> Exelixis <i>South San Francisco, CA</i>	solid tumors	Phase I (212) 546-4000

The content of this report has been obtained through public, government and industry sources and the Adis "R&D Insight" database based on the reports from PhRMA's "Medicines in Development" report series: **Cancer**, current as of March 2009; **Heart Disease and Stroke**, current as of January 2009; **HIV/AIDS**, current as of November 2008; **Older Americans**, current as of November 2008; **Mental Illness**, current as of May 2008; **Neurological Disorders**, current as of February 2008; **Infectious Diseases**, current as of October 2007; **Women**, current as of July 2007; **Children**, current as of March 2007; **Orphan Drugs (Rare Diseases)**, current as of January 2007. The information in this report may not be comprehensive. For more specific information about a particular product, contact the individual company directly or go to www.clinicaltrials.gov. The entire series of Medicines in Development is available on PhRMA's web site.

A publication of PhRMA's Communications & Public Affairs Department. (202) 835-3460

www.phrma.org | www.innovation.org | www.pparx.org | www.buysafedrugs.info | www.sharingmiracles.com

Provided as a Public Service by PhRMA. Founded in 1958 as the Pharmaceutical Manufacturers Association.

Copyright © 2009 by the Pharmaceutical Research and Manufacturers of America. Permission to reprint is awarded if proper credit is given.



New Medicines. New Hope.®

Pharmaceutical Research and Manufacturers of America
950 F Street, NW
Washington, DC 20004

www.phrma.org | www.innovation.org | www.pparx.org | www.buysafedrugs.info | www.sharingmiracles.com